Jula Inrig, M.D., joined Travere Therapeutics in January 2022 as the company’s chief medical officer. In this role, she is responsible for overseeing the company’s medical functions, clinical development, and clinical operations as well as drug safety/pharmacovigilance.
She brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution as well as global regulatory engagement. Prior to joining Travere, Dr. Inrig served as Global Head of the Renal Center of Excellence at IQVIA. While at IQVIA, Dr. Inrig was instrumental in the design, execution and strategy of clinical trials leading to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals in autosomal dominant polycystic kidney disease (ADPKD), and diabetic kidney disease. She was also responsible for the execution of more than 45 clinical trials across 50 countries, enrolling over 25,000 patients, including pivotal phase 3 trials in FSGS, IgAN and lupus nephritis. In addition to her roles at IQVIA, Dr. Inrig served as an inaugural member of the board for the Kidney Health Initiative, a public-private partnership with the FDA, founded with the goal of improving the development of therapies for patients with kidney disease. Dr. Inrig has also served in advisory roles for national societies and their guidelines including the American Society of Nephrology, the National Kidney Foundation, and the American Heart Association.
Dr. Inrig has been recognized by PharmaVOICE magazine as one of the “100 Most Inspiring People” in the life sciences industry, by Women We Admire as one of the “Top 50 Women Leaders of Los Angeles,” and by the Healthcare Businesswomen’s Association as a Luminary award winner.
Dr. Inrig is board certified in nephrology and internal medicine and serves on the faculty at the University of California, Irvine, and as an adjunct in the Department of Medicine at the Duke University School of Medicine. Dr. Inrig received her M.D. from Loma Linda University and completed her internal medicine residency, her nephrology fellowship and obtained a Master of Health Science at Duke University. Dr. Inrig holds a B.A. from California State University, Sacramento.
What is Jula Inrig's net worth?
The estimated net worth of Jula Inrig is at least $1.68 million as of February 3rd, 2025. Dr. Inrig owns 85,236 shares of Travere Therapeutics stock worth more than $1,681,706 as of March 15th. This net worth approximation does not reflect any other assets that Dr. Inrig may own. Learn More about Jula Inrig's net worth.
How do I contact Jula Inrig?
The corporate mailing address for Dr. Inrig and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at ir@retrophin.com. Learn More on Jula Inrig's contact information.
Has Jula Inrig been buying or selling shares of Travere Therapeutics?
In the last ninety days, Jula Inrig has sold $132,359.84 in Travere Therapeutics stock. Most recently, Jula Inrig sold 4,207 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $20.12, for a transaction totalling $84,644.84. Following the completion of the sale, the insider now directly owns 85,236 shares of the company's stock, valued at $1,714,948.32. Learn More on Jula Inrig's trading history.
Who are Travere Therapeutics' active insiders?
Travere Therapeutics' insider roster includes Steve Aselage (Director), Roy Baynes (Director), Sandra Calvin (CAO), Laura Clague (CFO), Christopher Cline (Chief Financial Officer), Eric Dube (CEO), Peter Heerma (Insider), Jula Inrig (Insider), Gary Lyons (Director), Jeffrey Meckler (Director), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.
Are insiders buying or selling shares of Travere Therapeutics?
During the last year, insiders at the sold shares 28 times. They sold a total of 329,186 shares worth more than $6,178,934.13. The most recent insider tranaction occured on February, 12th when SVP William E Rote sold 5,200 shares worth more than $122,356.00. Insiders at Travere Therapeutics own 3.8% of the company.
Learn More about insider trades at Travere Therapeutics. Information on this page was last updated on 2/12/2025.
